Vibliome is developing a new family of therapeutics for the treatment of cancer, contraception and other indications, based upon a novel, focused library of inhibitors of validated and promising kinase targets and their escape pathways.
Robert Goodwin, PhD
Chief Executive Officer
Gary Flynn, PhD
President & Chief Scientific Officer